That the Parliament congratulates the Cancer Research UK (CRUK) Glasgow RadNet team on receiving £1.5 million for radiotherapy research over the next five years; understands that its aim is to find new ways to increase the effectiveness of radiotherapy to improve outcomes for patients, particularly those with cancers that are hard to treat, such as lung cancer, glioblastoma, head and neck cancers, mesothelioma and cancers of the pancreas and rectum; believes that the RadNet Glasgow team is already making an important contribution to lung cancer research through the CRUK-funded CONCORDE trial, which is combining radiotherapy with new molecular-targeted drugs to improve treatment outcomes without worsening lung patients’ side effects; acknowledges that the funding will help to continue the work to bring the next generation of radiotherapy treatments to patients sooner, and recognises the aim to develop new radiotherapy technologies and treatment combinations to help more people survive cancer, with fewer side effects and to have a better quality of life after treatment.